The Breast Journal / 2022 / Article / Tab 2 / Research Article
The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute Table 2 The clinicopathological characteristics of the four ER/PR profiles of included patients.
ER+/RP+ (58.4%) ER+/RP− (7.6%) ER−/RP− (14.2%) ER−/RP+ (8.1%) valueCharacteristics Age groups at diagnosis ≤50 years 369 (55.4%) 36 (41%) 77 (49.7%) 48 (51.1%) >50 years 297 (44.6%) 52 (60%) 78 (50.3%) 46 (48.9%) Grade 1 78 (11.7%) 7 (8%) 2 (1.3%) 10 (10.6%) 2 368 (55.3%) 41 (46.6%) 55 (33.5%) 32 (34%) 3 165 (24.8%) 31 (35.2%) 87 (56.1%) 47 (50%) NA (8.2%) 10.2% 9% 5.4% Tumor size ≤2 cm 185 (36.3%) 22 (33.8%) 30 (24.2%) 18 (28.6%) >2 cm 305 (59.8%) 42 (64.6%) 89 (71.8%) 43 (68.3%) NA 3.9% 1.6% 4% 3% Lymph node status Positive 301 (45%) 38 (43%) 57 (40.2%) 29 (31.2%) Negative 142 (21.24%) 23 (26.1%) 53 (36.8%) 23 (24.5%) NA 66.2% 31% 23% 44% PtT 149 (22.1%) 17 (19.3%) 29 (17.7%) 15 (16%) T2 243 (36.1%) 32 (36.4%) 76 (46.3%) 27 (28.7%) T3 33 (5%) 8 (9.1%) 9 (5.5%) 7 (7.4%) T4 27 (4%) 5 (5.7%) 5 (3%) 7 (7.4%) NA 32% 29.5% 27.5% 40.5% HER2 status Negative 467 (20.7%) 48 (38.6%) 97 (31.6%) 54 (34%) Positive 138 (70.6%) 33 (53.4%) 49 (62%) 33 (59.6%) NA 8.7% 8% 6.4% 6.4% KI67 ≤20% 155 (28.6%) 16 (29.1%) 19 (17.9%) 11 (16%) >20% 387 (72%) 39 (70.9%) 87 (82.1%) 65 (84%)
NA: not available.